Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
0.945EUR
11.25 MEUR
169.63 MEUR
11.06 M
About BASILEA N
Sector
CEO
David Veitch
Headquarters
Allschwil
Website
Employees (FY)
147
Founded
2000
ISIN
CH0011432447
FIGI
BBG000N5LZC8
Basilea Pharmaceutica AG engages in the development and commercialization of pharmaceutical products. Its products include antifungals and antibiotics. The company was founded on October 17, 2000, and is headquartered in Allschwil, Switzerland.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on MUN exchange BASILEA PHARM.NA SF 1 stocks are traded under the ticker PK5.
We've gathered analysts' opinions on BASILEA PHARM.NA SF 1 future price: according to them, PK5 price has a max estimate of 94.95 EUR and a min estimate of 52.52 EUR. Watch PK5 chart and read a more detailed BASILEA PHARM.NA SF 1 stock forecast: see what analysts think of BASILEA PHARM.NA SF 1 and suggest that you do with its stocks.
Yes, you can track BASILEA PHARM.NA SF 1 financials in yearly and quarterly reports right on TradingView.
BASILEA PHARM.NA SF 1 is going to release the next earnings report on Aug 13, 2024. Keep track of upcoming events with our Earnings Calendar.
PK5 earnings for the last quarter are −1.83 EUR per share, whereas the estimation was −2.16 EUR resulting in a 14.96% surprise. The estimated earnings for the next quarter are 1.20 EUR per share. See more details about BASILEA PHARM.NA SF 1 earnings.
BASILEA PHARM.NA SF 1 revenue for the last quarter amounts to 78.41 M EUR despite the estimated figure of 77.41 M EUR. In the next quarter revenue is expected to reach 92.96 M EUR.
PK5 net income for the last quarter is −23.02 M EUR, while the quarter before that showed 32.60 M EUR of net income which accounts for −170.61% change. Track more BASILEA PHARM.NA SF 1 financial stats to get the full picture.
No, PK5 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jun 3, 2024, the company has 147.00 employees. See our rating of the largest employees — is BASILEA PHARM.NA SF 1 on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. BASILEA PHARM.NA SF 1 EBITDA is 24.41 M EUR, and current EBITDA margin is 14.39%. See more stats in BASILEA PHARM.NA SF 1 financial statements.
Like other stocks, PK5 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade BASILEA PHARM.NA SF 1 stock right from TradingView charts — choose your broker and connect to your account.